Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy

JAMA

Volumn 283, Issue 2, 2000, Pages 205-211

  Descamps, Diane ^a   Flandre, Philippe ^d   Calvez, Vincent ^b   Peytavin, Gilles ^a   Meiffredy, Vincent ^d   Collin, Gilles ^a   Delaugerre, Constance ^b   Robert Delmas, Sandrine ^d   Bazin, Brigitte ^d   Aboulker, Jean Pierre ^d   Pialoux, Gilles ^c   Raffi, François ^e   Brun Vézinet, Françoise ^a  

^a BICHAT HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HÔPITAL ROTHSCHILD   (France)

^d INSERM   (France)

^e HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LAMIVUDINE; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD SAMPLING; DRUG EFFECT; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT FAILURE; VIROLOGY; VIRUS LOAD; VIRUS REPLICATION;

EID: 0034639473     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.2.205     Document Type: Article

References (24)

1. Pialoux G, Raffi F, Brun-Vézinet F, et al. A randomized trial of three maintenace regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. N Engl J Med. 1998;339: 1269-1276.
2. Haviir DV, Marschner IC, Hirsch MS, et al. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple drug therapy. N Engl J Med. 1998;339:1261-1268.
3. Keijers MH, Weverling GJ, Jurriaans S, et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals. Lancet. 1998;352:185-193.
4. Chimeck N, Mundere J, Kabeya K, et al. MIRO, a randomized trial of maintence therapy with or without protease inhibitors after 4 months of triple or quadruple induction therapy. Presented at the 6th Conference on Retroviruses and Opportunitic Infections. January 31-February 4, 1993, Chicago, Ill. Abstract 523.
5. Clayvert L, Wyseur A, Rombout A, et al. Link probe assay for rapid detection odf drug selected mutations in the human immunodeficiency virus type 3 reverse transcriptase gene. Antimicrob Agents Chemother. 1997;83:383-391.
6. Nigraist M, Brusher CA, Schuurman R. Severe procedure for the amplification of HIV-1 RNA using a combined reverse-transcription and amplification reaction. Biotechniques. 1995;19:178-180, 182.
7. Nijlius M, Boucher CA, Scipper P, Callner T, Schuurman R, Albert J. Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proc Natl Acad Sci U S A. 1998;99: 14441-14448.
8. Larder BA, Kemp SD, Harrigan PR. Paternal mechanism for sustained antiretroviral efficacy of AZY-3TC combination therapy. Science. 1995;269:696-699.
9. Soussan P, Collin G, Descamps D, Foiny P, Bru-Vézinet F. Detection of M184V 3TC mutation in the HIV1 RT gene by Restriction Fragment Digestion Assay (RFDA). Presented at the 4th Conference on Retroviruses and Opportunistic Infections: Washington, DC; January 22-26, 1997. Abstract 634.
10. Woolf E, Au F, Haddix R, Matuszewski B. Determination of L-735 523, as human immunodeficiency virus protease inhibitor, human plasma and urine via high performance liquid chemotheraphy with column switching. J Chromatogr A. 1993;692:45-52.
11. Hoetelmans RM, Reijers MH, Weverling GJ, et al. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS. 1998;13:F111-F115.
12. Hochberg Y, Turrinane AC. A sharper Bonferroni procedure for multiple significance testing. Biometrika. 1988;75:800-803.
13. Hirsch MS, Conway B, D'Aguila BT, et al. Antiretroviral drug resistance testing in adults with HIV infection. JAMA. 1998;279:1984-1991.
14. Groska JH, Holder DJ, Schleif WA, et al. Genetic correlates of in vivo resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol. 1996;70:827-8276.
15. Brun-Vézinet F, Calvez V, Descamps O, et al. M184V mutation is not pridictive of therapeutic faillure to d4T/3TC combination. Presented at the 12th International Conference on AIDS, June 28-July 3, 1998; Geneva, Switzerland. Abstract 32310.
16. Paes AH, Bakker A, Soe-Agnie CJ. Measurement of patient compliance. Pharm World Sci. 1998;20: 73-77.
17. + cells per cubic millimeter. N Engl J Med. 1995;333:1662-1663.
18. Dfusano GL, Bilello JA, Stein DS, et al. Factors influencing the emergence of resistance to indinavir role of virologic, immunologic, and pharmacologic variables. J Infect Dis. 1998;178:360-367.
19. De Pasquale MP, Murphy R, Kuritzkes D, et al. Resistance during early virological rebound on amindinavir plus zidovudine plus lamivudine triple therapy in ampunavir monotherapy in ACTG protocol 347. Presented at 2nd International Workshop on HIV Drug Resistance and Treatment Strategies. June 14-23, 1998; Lake Maggiore, Italy. Abstract 21.
20. Calvez, V, Mouroux M, Yvon-Carrousel A, et al. Early virologic failures in HIV-infected male patients receiving saquinavir-SGC in combination with d4T/ d3C IMACADO trial, Roche M6110023 genotype phenologic resistance anaysis and drug measurement study. Presented at International Conference on the Discovery and Clinical Development of Antiretoviral Therapy, December 13-17, 1998; St. Thomas, West India. Abstract 19.
21. Young B, Johnson S, Bahktian M, et al. Resistance mutations in protease an reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure. J Infect Dis. 1998;178:1497-1501.
22. Mayers DL, Gallahan DL, Martin GI, et al. Drug resistance genotypes from plasma virus of HIV-infected patients failing combination drug therapy [abstract]. Antiviral Ther. 1997;Abstract 9372.
23. Johnson VA, Nail CD, Hazelwassel JO, et al. Multidrug-resistant HIV-1 isolates from patients with rising plasma viral burden during double or triple combination therapy in clinical practice [abstract]. Antiviral Ther. 1997;2(suppl 5):72.
24. Hastli DB, Petropoulos CJ, Hellman N, Whitcomb JM, Richman DD, and the ACTG 343 team. Evolution of drug resistance associated with loss of viral suppresion in patients treated with indinavir, lamivudine and zidovudine. Presented at 2nd International Workshop on HIV Drug Resistane and Treatment Strategies, June 24-27, 1998; Lake Maggiore, Italy. Abstract 74.